FDA Clears Phase 3b Trial of NurOwn for ALS

The new therapy was applied in only 12 patients and developed in the United States. It allowed reversing the effects of one of the most aggressive variants of amyotrophic lateral sclerosis, according to a study published in The Lancet

The project prepared in Samsun aims to prevent the progression of the nervous system disease ALS (Amyotrophic Lateral Sclerosis).

FDA clears Phase 3b trial of NurOwn for ALS

The U.S. Food and Drug Administration (FDA) has cleared a Phase 3b clinical trial to test Brainstorm Cell Therapeutics’ cell-based therapy NurOwn (debamestrocel) in people with amyotrophic lateral sclerosis (ALS). The trial, ENDURANCE (NCT06973629), is expected to open soon at more than a dozen sites across the U.S. It plans to recruit about 200 adults with moderate disease who have been experiencing symptoms of ALS, including muscle weakness, f…

A door open to the hope of some patients with amyotrophic lateral sclerosis (ALS). A treatment tested in a small group of patients has resulted in improvements in some of them. A young woman, who was in a wheelchair and needed the use of a respirator for her day to day, has managed to walk without help. Since the end of 2020 she was being treated with the experimental drug, which has been tested with those affected by mutations of the FUS gene, …